STOCK TITAN

Equillium (EQ) SEC Filings

EQ NASDAQ

Equillium, Inc. filings document a clinical-stage biotechnology issuer focused on therapies for severe autoimmune and inflammatory disorders. The company’s disclosures cover EQ504, an investigational AhR modulator, along with operating results, financial condition, research and development priorities, and capital resources tied to biotechnology development.

Regulatory filings include 8-K material-event reports, proxy materials, and registration-related disclosures. These records address annual-meeting matters, board and compensation governance, equity awards, auditor changes, common-stock offering documents, material agreements, shareholder voting matters, and capital-structure information for EQ common stock listed on the Nasdaq Capital Market.

Schedule 13G/A
Rhea-AI Summary

Equillium, Inc. (EQ) is the issuer of 2,613,954 common shares beneficially owned as of September 30, 2026, as reported by Affinity Asset Advisors, LLC and Michael Cho, the adviser’s managing member. Affinity Healthcare Fund, LP directly holds the shares; Affinity Asset Advisors is the fund’s investment manager and exercises voting and investment power under an investment management agreement.

Each reporting person reported sole voting and dispositive power over the shares, with no shared voting or dispositive power. The reported stake is approximately 4.1% of Equillium’s common stock, based on 63,408,082 shares outstanding as of August 7, 2026. Cho may be deemed a beneficial owner through his position as managing member; the reported ownership is 5% or less.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ownership
-
Rhea-AI Summary

Equillium, Inc. (EQ) seeks to register for resale by selling stockholders up to 35,087,717 shares of common stock, including 20,130,457 shares issuable upon exercise of pre-funded warrants. The selling stockholders may not sell until the registration statement is effective. Equillium is not selling shares and will receive no proceeds from resales; it would receive the $0.0001-per-share exercise price if holders exercise the warrants for cash.

At the milestone closing on October 26, 2026, Equillium sold and issued 14,957,260 common shares and warrants to purchase 20,130,457 shares. The purchase price at that closing was approximately $20.0 million, and gross proceeds across the initial and milestone closings were approximately $50.0 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
registration
-
Rhea-AI Summary

Equillium, Inc. reported a $14.587 million net loss for the nine months ended September 30, 2026, compared with $18.623 million a year earlier. Cash used in operations was $12.233 million, down from $19.613 million, and cash and cash equivalents totaled $53.322 million at September 30. The clinical-stage biotechnology company reported no product sales and an accumulated deficit of $230.792 million.

Research and development expenses were $8.228 million for nine months, versus $11.307 million a year earlier, but rose to $2.488 million in the third quarter from $1.301 million; the company cited increased EQ504 development activity among the reasons. On October 26, after the first patient was dosed in an EQ504 single ascending dose trial in Australia and investors waived the price threshold, Equillium completed the milestone closing. It issued 14,957,260 common shares and pre-funded warrants for 20,130,457 shares, for approximately $20.0 million in gross proceeds before fees. Management says cash at September 30 plus net proceeds from the closing are expected to fund operations into 2029, based on assumptions that may prove inaccurate. The company also reported $75.0 million available to sell under its ATM facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
quarterly report
Rhea-AI Summary

Equillium, Inc. reported a third-quarter 2026 net loss of $4.6 million, or $(0.04) per basic and diluted share, versus a $4.2 million net loss, or $(0.06) per share, in 2025. R&D expense was $2.5 million versus $1.3 million; G&A expense was $2.6 million versus $3.3 million. Cash and equivalents were $53.3 million as of September 30, 2026. The October 26 private-placement tranche generated approximately $20 million in gross proceeds; pro forma cash after estimated net proceeds was approximately $72.0 million as if received September 30, excluding cash used thereafter. Equillium expects cash and October funding to support planned operations into 2029.

In October 2026, Equillium initiated a randomized, double-blind, placebo-controlled Phase 1 trial of EQ504 in Australia, evaluating single and multiple ascending doses in approximately 70 healthy participants. The trial assesses safety, tolerability, pharmacokinetics and pharmacodynamics and is designed to establish proof of mechanism. Multiple-dose participants undergo gastrointestinal mucosal biopsies, including CYP1A1 measurement. Topline data are expected in Q2 2027. Subject to supportive results, Equillium plans a placebo-controlled proof-of-concept study in moderately to severely active ulcerative colitis in the second half of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
current report
-
Rhea-AI Summary

Equillium, Inc. is named in an amended ownership report listing the same 3,966,917-share beneficial ownership position, or 5.93%, for Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross. The position includes 3,442,514 shares issuable upon exercise of warrants held directly by Adage Capital Partners, L.P.

Each reporting person is shown with shared voting and dispositive power over 3,966,917 shares and zero sole voting or dispositive power. Adage Capital Management is identified as investment manager of Adage Capital Partners; Atchinson and Gross are identified in managing-member capacities. The percentage calculation uses 63,408,082 shares outstanding as of August 7, 2026, and assumes exercise of the warrants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.04%
Tags
ownership
-
Rhea-AI Summary

Equillium, Inc. (EQ) is the subject of an amended beneficial-ownership report by Aberdeen Group plc and abrdn Inc., each reporting 4,458,351 common shares, or 7.03% of the class. Both report shared voting and shared dispositive power over those shares. Aberdeen Group plc is identified as the parent, abrdn Holdings Limited as the intermediate holding company, and abrdn Inc. as beneficially owning the shares on behalf of underlying clients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
ownership
Rhea-AI Summary

Equillium, Inc. completed its milestone closing on October 26, 2026, after the first EQ504 subject was dosed and the requisite investors waived the price-threshold requirement. It issued 14,957,260 common shares at $0.57 per share and 20,130,457 pre-funded warrants at $0.5669 per warrant, receiving $20.0 million in gross proceeds. Equillium expects its cash and cash equivalents to fund currently planned operations into 2029.

EQ504’s Phase 1 trial in Australia is designed to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics in approximately 70 healthy subjects, using once-daily oral doses of 0.1–3.0 mg. Topline proof-of-mechanism data are anticipated in Q2 2027. Subject to supportive Phase 1 data, Equillium anticipates starting a placebo-controlled proof-of-concept study in patients with moderately to severely active ulcerative colitis in the second half of 2027. The warrants have a $0.0001 exercise price and a beneficial-ownership limitation not to exceed 19.99%. Equillium agreed to file resale registration statements within 30 days of closing, subject to allowable delays.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.80%
Tags
current report
-
Rhea-AI Summary

Equillium, Inc. received Human Research Ethics Committee approval and Therapeutic Goods Administration clearance in Australia under the Clinical Trial Notification scheme for its Phase 1 EQ504 trial. The company expects to begin dosing healthy participants by early November 2026.

The randomized, double-blinded, placebo-controlled, single-center study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics using once-daily oral doses ranging from 0.1 to 3.0 mg. The trial is structured in three parts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
current report
-
Rhea-AI Summary

Equillium, Inc. is a clinical‑stage biotechnology company developing therapies for severe autoimmune and inflammatory disorders, primarily its novel aryl hydrocarbon receptor modulator EQ504 and preclinical candidate EQ302. For the six months ended June 30, 2026, it reported a net loss of $10.0 million, improved from $14.4 million in 2025, driven largely by lower research and development spending following the wind down of the EQUATOR study.

Cash and cash equivalents were $57.2 million at June 30, 2026, up from $30.3 million at December 31, 2025, reflecting net $34.8 million of proceeds from a March 2026 private placement of common stock and pre‑funded warrants. Total stockholders’ equity increased to $56.0 million and accumulated deficit reached $226.2 million.

Management expects existing cash to fund operations into 2029 and at least 12 months from the filing date. The company plans to initiate a Phase 1 placebo‑controlled proof‑of‑mechanism study of EQ504 in the fourth quarter of 2026, with data anticipated about six months later, and maintains additional potential financing capacity via a $75.0 million at‑the‑market facility and up to $20.0 million of contingent August 2025 private placement proceeds tied to clinical and stock‑price milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.41%
Tags
quarterly report
Rhea-AI Summary

Affinity Asset Advisors, LLC and its managing member Michael Cho report beneficial ownership of Equillium Inc. common stock. As of June 30, 2026, they beneficially own 4,100,000 shares of Equillium common stock, representing 6.5% of the shares outstanding, held through Affinity Healthcare Fund, LP. They have sole voting and dispositive power over these 4,100,000 shares and no shared voting or dispositive power. The ownership percentage is based on 63,226,556 shares of Equillium common stock outstanding as of May 8, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.41%
Tags
ownership

FAQ

How many Equillium (EQ) SEC filings are available on StockTitan?

StockTitan tracks 72 SEC filings for Equillium (EQ), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Equillium (EQ)?

The most recent SEC filing for Equillium (EQ) was filed on November 13, 2026.